高级搜索
安瘤乳治疗恶性肿瘤的临床总结[J]. 肿瘤防治研究, 1987, 14(3): 146-148.
引用本文: 安瘤乳治疗恶性肿瘤的临床总结[J]. 肿瘤防治研究, 1987, 14(3): 146-148.
CLINICAL TRIAL OF "AN LIU RU" ON MALIGNANCIES[J]. Cancer Research on Prevention and Treatment, 1987, 14(3): 146-148.
Citation: CLINICAL TRIAL OF "AN LIU RU" ON MALIGNANCIES[J]. Cancer Research on Prevention and Treatment, 1987, 14(3): 146-148.

安瘤乳治疗恶性肿瘤的临床总结

CLINICAL TRIAL OF "AN LIU RU" ON MALIGNANCIES

  • 摘要: 安瘤乳为沈阳药学院和河南省安阳市第一制药厂研制的一种新剂型抗癌药物,经动物实验证明具一定的抗癌作用和特点,且副作用小。自1982年8月至1984年12月由全国26家医院治疗各种恶性肿瘤243例,还有74例仅对药物的副作用作了观察,总观察病例数为317例,现将其结果总结如下。

     

    Abstract: 317 patients of malignancies were treated by"An Liu Ru" (ALR) (5-fluorouracil composite emulsion) in 26 hospitals. ALR was given intravenously with a daily dose of 10~50ml,the range of total dose was 400~2450ml; or orally with a daily dose of 30~60ml, the range of total dose was 600~7320ml, The response rates(PR+MR) OF ALR were 23%,21%,8% and 7% respectively on cancer of bowel,stomach. esophageal and cardia. The object response rates were 31%,30%,12% and 11% respectively for those cancer just mentioned above.The symptomatic and objective response rates were62%,58%,42% and 24% respectively.The side effects were anorexia,nausea,vomiting and phlebitis in a few patients The effect of ALR on alimentary tract cancer was better,and the side effect was small.

     

/

返回文章
返回